SCHEMBL2689072

SCHEMBL2689072

CNC(CCS)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1270687 1.00
SCHEMBL2006468 1.00
Homocysteine SCHEMBL18770054 0.88 PTGS1 (0.43)
SCHEMBL31642611 0.86 FOLH1 (0.44)
SCHEMBL31641357 0.86 FOLH1 (0.44)
SCHEMBL18881182 0.81
SCHEMBL19862685 0.81
SCHEMBL12681624 0.81
SCHEMBL120068 0.80
SCHEMBL120067 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114907546-B Multifunctional polyurea acid ester derivative and preparation method and application thereof 四川大学 2023-06-02 CN claimed
CN-103122365-A Target gene Rv3290c for screening antituberculous inhibitor and application UNIV HUAZHONG AGRICULTURAL 2013-05-29 CN claimed
WO-2010126552-A1 POTENT CELL-BINDING AGENT DRUG CONJUGATES IMMUNOGEN, INC. (US) 2010-11-04 WO claimed
US-20100092495-A1 POTENT CELL-BINDING AGENT DRUG CONJUGATES IMMUNOGEN INC. (US) 2010-04-15 US claimed
US-7659364-B2 N-methyl-homocysteines and their use as well as process for their production CIS BIO INTERNATIONAL (FR) 2010-02-09 US claimed
EP-1444194-B1 N-METHYL-HOMOCYSTINES, USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF CIS BIO INT (FR) 2009-12-09 EP claimed
CN-1304363-C N-methyl-homocysteines and their use as well as process for their production CIS BIOLOGY INTERNAT CO (FR) 2007-03-14 CN claimed
CN-1589257-A N-methyl-homocysteine and application and preparation method thereof SCHERING AG (DE) 2005-03-02 CN claimed
US-20030120032-A1 N-methyl-homocysteines and their use as well as process for their production SCHERING AG (DE) 2003-06-26 US claimed
US-20250222146-A1 Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof RAYZEBIO, INC. (US) 2025-07-10 US disclosed
WO-2025137443-A1 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING SOMATOSTATIN RECEPTORS AND USES THEREOF RAYZEBIO, INC. (US) 2025-06-26 WO disclosed
WO-2025137441-A1 RADIOPHARMACEUTICALS TARGETING SOMATOSTATIN RECEPTOR 2 AND USES THEREOF RAYZEBIO, INC. (US) 2025-06-26 WO disclosed
US-20250057957-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2025-02-20 US disclosed
EP-4483875-A2 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 Therapeutics, Inc. (US) 2025-01-01 EP disclosed
WO-2001044177-A2 SOMATOSTATIN ANALOGS, RADIOLABELLED DERIVATIVES THEREOF AND THEIR USE SCHERING AKTIENGESELLSCHAFT (DE) 2001-06-21 WO disclosed
WO-2001024763-A2 COMPOSITIONS AND METHODS FOR TREATING CANCER USING IMMUNOCONJUGATES AND CHEMOTHERAPEUTIC AGENTS IMMUNOGEN, INC. (US) 2001-04-12 WO disclosed
EP-0425235-B1 Cytotoxic agents comprising maytansinoids and their therapeutic use IMMUNOGEN INC (US) 1996-09-25 EP disclosed
US-5416064-A Antitumor agents IMMUNOGEN, INC. (US) 1995-05-16 US disclosed
US-5208020-A Cytotoxic agents comprising maytansinoids and their therapeutic use IMMUNOGEN INC. (US) 1993-05-04 US disclosed
EP-0425235-A2 Cytotoxic agents comprising maytansinoids and their therapeutic use IMMUNOGEN INC (US) 1991-05-02 EP disclosed